Skip to main content

Expression Analysis Teams with Illumina, Golden Helix on Grant Program

Premium

Expression Analysis announced yesterday that it has teamed up with Illumina and Golden Helix on an RNA-seq grant program.

Under the program, Expression Analysis will perform the sequencing and provide primary and secondary data analysis, while Golden Helix will provide cloud-based secondary analysis tools and storage as well as end-user tertiary analysis tools. Illumina will provide the products for the studies, Expression Analysis said.

One grant will be awarded for each category: biomarker discovery using whole-transcriptome sequencing; developmental coding and non-coding RNA expression; and RNA-seq analysis of FFPE samples.

Applications for the grants are due April 13, and recipients will be notified no later than May 15. More information about the grant program can be found on Expression Analysis' website.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.